Autoimmune pancreatitis in the USA

R. P. Sah, N. Ahmed, P. A. Hart, Suresh T Chari

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Autoimmune pancreatitis (AIP) is a recently recognized disease affecting the pancreas. It closely mimics pancreatic cancer in presentation. In fact, pancreatic resections performed for presumed pancreatic cancer have historically played a key role in recognition of this disease entity. Characterized by distinct histological features in the pancreas which has formed the basis of diagnosis for a majority of patients historically, increased recognition of this disease has led to development of diagnostic criteria. In the USA, the HISORt criteria introduced in 2006 has formed the backbone of diagnosing this disease. Recently, international consensus criteria have been developed incorporating experiences and practices from across the world. With increasing experience of this disease, treatment and follow-up strategies have now emerged. The disease is characteristically responsive to steroid treatment. However, relapses are common. Interestingly, two groups of AIP patients were observed with distinct patterns of relapse and corresponding distinctive histological and clinical features. This led to subclassification of AIP into two subtypes: type 1 in which relapses are common and histologically corresponding to lymphoplasmacytic sclerosing pancreatitis (LPSP) with IgG4 positivity and type 2 in which relapses are rare and histologically characterized by granulocyte epithelial lesions (GELs). Long-term follow-up data have now established that despite relapses, AIP is a benign disease which does not affect overall survival.

Original languageEnglish (US)
Title of host publicationAutoimmune Pancreatitis
PublisherSpringer Berlin Heidelberg
Pages189-195
Number of pages7
ISBN (Print)9783642550867, 9783642550850
DOIs
StatePublished - Jan 1 2015

Fingerprint

Pancreatitis
Recurrence
Pancreatic Neoplasms
Pancreas
Granulocytes
Immunoglobulin G
Steroids
Survival
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sah, R. P., Ahmed, N., Hart, P. A., & Chari, S. T. (2015). Autoimmune pancreatitis in the USA. In Autoimmune Pancreatitis (pp. 189-195). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-55086-7_28

Autoimmune pancreatitis in the USA. / Sah, R. P.; Ahmed, N.; Hart, P. A.; Chari, Suresh T.

Autoimmune Pancreatitis. Springer Berlin Heidelberg, 2015. p. 189-195.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sah, RP, Ahmed, N, Hart, PA & Chari, ST 2015, Autoimmune pancreatitis in the USA. in Autoimmune Pancreatitis. Springer Berlin Heidelberg, pp. 189-195. https://doi.org/10.1007/978-3-642-55086-7_28
Sah RP, Ahmed N, Hart PA, Chari ST. Autoimmune pancreatitis in the USA. In Autoimmune Pancreatitis. Springer Berlin Heidelberg. 2015. p. 189-195 https://doi.org/10.1007/978-3-642-55086-7_28
Sah, R. P. ; Ahmed, N. ; Hart, P. A. ; Chari, Suresh T. / Autoimmune pancreatitis in the USA. Autoimmune Pancreatitis. Springer Berlin Heidelberg, 2015. pp. 189-195
@inbook{2beeab03a4db47a4bdd3c42f11693182,
title = "Autoimmune pancreatitis in the USA",
abstract = "Autoimmune pancreatitis (AIP) is a recently recognized disease affecting the pancreas. It closely mimics pancreatic cancer in presentation. In fact, pancreatic resections performed for presumed pancreatic cancer have historically played a key role in recognition of this disease entity. Characterized by distinct histological features in the pancreas which has formed the basis of diagnosis for a majority of patients historically, increased recognition of this disease has led to development of diagnostic criteria. In the USA, the HISORt criteria introduced in 2006 has formed the backbone of diagnosing this disease. Recently, international consensus criteria have been developed incorporating experiences and practices from across the world. With increasing experience of this disease, treatment and follow-up strategies have now emerged. The disease is characteristically responsive to steroid treatment. However, relapses are common. Interestingly, two groups of AIP patients were observed with distinct patterns of relapse and corresponding distinctive histological and clinical features. This led to subclassification of AIP into two subtypes: type 1 in which relapses are common and histologically corresponding to lymphoplasmacytic sclerosing pancreatitis (LPSP) with IgG4 positivity and type 2 in which relapses are rare and histologically characterized by granulocyte epithelial lesions (GELs). Long-term follow-up data have now established that despite relapses, AIP is a benign disease which does not affect overall survival.",
author = "Sah, {R. P.} and N. Ahmed and Hart, {P. A.} and Chari, {Suresh T}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-642-55086-7_28",
language = "English (US)",
isbn = "9783642550867",
pages = "189--195",
booktitle = "Autoimmune Pancreatitis",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Autoimmune pancreatitis in the USA

AU - Sah, R. P.

AU - Ahmed, N.

AU - Hart, P. A.

AU - Chari, Suresh T

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Autoimmune pancreatitis (AIP) is a recently recognized disease affecting the pancreas. It closely mimics pancreatic cancer in presentation. In fact, pancreatic resections performed for presumed pancreatic cancer have historically played a key role in recognition of this disease entity. Characterized by distinct histological features in the pancreas which has formed the basis of diagnosis for a majority of patients historically, increased recognition of this disease has led to development of diagnostic criteria. In the USA, the HISORt criteria introduced in 2006 has formed the backbone of diagnosing this disease. Recently, international consensus criteria have been developed incorporating experiences and practices from across the world. With increasing experience of this disease, treatment and follow-up strategies have now emerged. The disease is characteristically responsive to steroid treatment. However, relapses are common. Interestingly, two groups of AIP patients were observed with distinct patterns of relapse and corresponding distinctive histological and clinical features. This led to subclassification of AIP into two subtypes: type 1 in which relapses are common and histologically corresponding to lymphoplasmacytic sclerosing pancreatitis (LPSP) with IgG4 positivity and type 2 in which relapses are rare and histologically characterized by granulocyte epithelial lesions (GELs). Long-term follow-up data have now established that despite relapses, AIP is a benign disease which does not affect overall survival.

AB - Autoimmune pancreatitis (AIP) is a recently recognized disease affecting the pancreas. It closely mimics pancreatic cancer in presentation. In fact, pancreatic resections performed for presumed pancreatic cancer have historically played a key role in recognition of this disease entity. Characterized by distinct histological features in the pancreas which has formed the basis of diagnosis for a majority of patients historically, increased recognition of this disease has led to development of diagnostic criteria. In the USA, the HISORt criteria introduced in 2006 has formed the backbone of diagnosing this disease. Recently, international consensus criteria have been developed incorporating experiences and practices from across the world. With increasing experience of this disease, treatment and follow-up strategies have now emerged. The disease is characteristically responsive to steroid treatment. However, relapses are common. Interestingly, two groups of AIP patients were observed with distinct patterns of relapse and corresponding distinctive histological and clinical features. This led to subclassification of AIP into two subtypes: type 1 in which relapses are common and histologically corresponding to lymphoplasmacytic sclerosing pancreatitis (LPSP) with IgG4 positivity and type 2 in which relapses are rare and histologically characterized by granulocyte epithelial lesions (GELs). Long-term follow-up data have now established that despite relapses, AIP is a benign disease which does not affect overall survival.

UR - http://www.scopus.com/inward/record.url?scp=84956621838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956621838&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-55086-7_28

DO - 10.1007/978-3-642-55086-7_28

M3 - Chapter

AN - SCOPUS:84956621838

SN - 9783642550867

SN - 9783642550850

SP - 189

EP - 195

BT - Autoimmune Pancreatitis

PB - Springer Berlin Heidelberg

ER -